NewAmsterdam Pharma (NAMS) Current Assets (2021 - 2026)

NewAmsterdam Pharma has disclosed Current Assets across 6 years of filings, most recently posting $658.0 million for Q1 2026.

• Current Assets for Q1 2026 came in at $658.0 million, down 19.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $658.0 million (down 19.49% YoY), and the FY2025 annual result was $675.7 million, down 21.74% from the prior year.
• Current Assets came in at $658.0 million for Q1 2026 at NewAmsterdam Pharma, down from $675.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $863.4 million in Q4 2024 to a low of $346.8 million in Q4 2023.
• The 5-year median for Current Assets is $572.9 million (2024), against an average of $593.0 million.
• Across the five-year window, Current Assets soared 578.85% in 2022 and slipped 24.15% in 2023, its largest moves.
• NewAmsterdam Pharma's Current Assets stood at $457.2 million in 2022, then fell by 24.15% to $346.8 million in 2023, then surged by 148.97% to $863.4 million in 2024, then retreated by 21.74% to $675.7 million in 2025, then retreated by 2.61% to $658.0 million in 2026.
• The last three Current Assets figures came in at $658.0 million (Q1 2026), $675.7 million (Q4 2025), and $732.3 million (Q3 2025), per Business Quant data.